SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: idahoranch1 who wrote (45900)4/25/2018 5:02:06 PM
From: idahoranch114 Recommendations

Recommended By
bobbseytwins2001
captcobra1
corndog
dorightbythem
drtom1234

and 9 more members

   of 63276
 
A while back I suggested that when Michael Pehl commented in a CC a few months ago that they were evaluating data from over 70 patients with erMBC, that maybe they pulled all those patients from all the breast cancer patients, including the TNBC patients, to get this data. It was point out to me that TNBC patients are negative HR and in fact are negative 3 primary targets.
So the data we will get in the oral presentation appears to be to be from over 70 patients in the basket trial but they were recruited to investigate 132’s efficacy in HR+MBC. This makes this higher quality data than I was anticipating.
The clock is ticking towards some milestones. The abstracts on May 16th, AA filing shortly after and presentation of HR+ MBC Sunday June 3rd and investor meeting that night as well.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News